Nalpain (Nalbuphine Hydrochloride)

Nalbuphine Hydrochloride, the active ingredient in Nalpain, is an opioid analgesic presented as a sterile injectable solution for intramuscular, intravenous, and subcutaneous use. It provides analgesia for moderate to severe pain in adult patients, including postoperative and obstetric settings. The drug acts rapidly after administration and is formulated for use in hospital environments where precise dosing and monitoring are required. It is supplied in vials that comply with pharmaceutical standards. Nalpain is intended for administration by qualified healthcare professionals under appropriate clinical supervision.

GNH USA supplies Nalpain as a licensed, GDP‑compliant pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nalpain (nalbuphine hydrochloride) is used in clinical settings to manage pain through its action on opioid receptors.

- Postoperative pain: Provides effective analgesia for moderate to severe pain following surgical procedures. - Acute trauma pain: Controls pain associated with injuries such as fractures or burns. - Obstetric analgesia: Used to relieve labor pain while maintaining maternal and fetal safety. - Cancer-related pain: Offers analgesic relief for patients with malignant disease when other opioids are insufficient. - Visceral pain: Reduces intense abdominal or pelvic pain that does not respond well to conventional opioids.

Nalbuphine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Vomiting: occasional episodes. - Dizziness: transient light‑headedness. - Sedation: drowsiness or reduced alertness. - Pruritus: itching, especially at injection site. - Sweating: increased perspiration.

Serious or Rare Side Effects: - Respiratory depression: reduced breathing effort, potentially life‑threatening. - Hypotension: significant drop in blood pressure. - Bradycardia: abnormally slow heart rate. - Allergic reactions: rash, urticaria, or anaphylaxis. - Seizures: rare convulsive events.

When using Nalpain, clinicians should observe specific precautions to ensure patient safety and maintain drug integrity. - Patient assessment: evaluate pain level, opioid tolerance, and medical history before initiating therapy. - Respiratory monitoring: observe for signs of respiratory depression, especially in opioid‑naïve patients. - Concomitant CNS depressants: avoid or use with caution when combined with alcohol, benzodiazepines, or other sedatives. - Renal or hepatic impairment: adjust dosing and monitor closely in patients with liver or kidney dysfunction. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nalbuphine can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Opioid antagonists (e.g., naloxone, naltrexone): may reverse analgesic effect and precipitate withdrawal. - CNS depressants (e.g., barbiturates, high‑dose benzodiazepines): can enhance sedation and respiratory depression. - MAO inhibitors: concurrent use may increase risk of severe hypotension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - Other opioids: additive effects may increase sedation and respiratory compromise. - Anticholinergic agents: may exacerbate constipation and urinary retention. - CYP3A4 inhibitors/inducers: may affect nalbuphine metabolism, requiring dose adjustment.